20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
12:30 MIN
- CIDP
Understand the challenges associated with accurately diagnosing CIDP
Clinical Studies for the Treatment of CIDP with Immunoglobulin
9:35 MIN
- CIDP
Learn about clinical studies for the treatment of CIDP with immunoglobulin.
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
12:50 MIN
- CIDP
- MMN
Review options for individualizing treatment and tools used to assess IgG performance
NOW PLAYING
15:31
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
NOW PLAYING
12:30
Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
Understand the challenges associated with accurately diagnosing CIDP
NOW PLAYING
9:35
Clinical Studies for the Treatment of CIDP with Immunoglobulin
Learn about clinical studies for the treatment of CIDP with immunoglobulin.
NOW PLAYING
12:50
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
Review options for individualizing treatment and tools used to assess IgG performance
Our Experts on CIDP
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
- CIDP
Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
- CIDP
- GBS
- MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
- CIDP
- MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
- CIDP
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.
Slides & Posters about CIDP
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies
PDF | 680 KB
IgG Levels and Wear Off Reflect Administration and Outcome
PDF | 1.5 MB
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
PDF | 2.35 MB
Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing
PDF | 1.4 MB
Back to Top